Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 100.00% | 97.14% | 98.11% | -- |
| Gross Profit | -- | -100.00% | -98.19% | -98.90% | 44.00% |
| SG&A Expenses | 235.28% | 89.56% | 56.65% | 27.12% | 9.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.70% | 40.18% | 10.74% | 9.57% | 17.40% |
| Operating Income | -85.70% | -40.22% | -11.05% | -9.97% | -17.87% |
| Income Before Tax | -74.32% | -22.12% | 1.81% | -2.12% | -11.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.32% | -22.12% | 1.81% | -2.12% | -11.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.32% | -22.12% | 1.81% | -2.12% | -11.19% |
| EBIT | -85.70% | -40.22% | -11.05% | -9.97% | -17.87% |
| EBITDA | -86.13% | -40.40% | -11.10% | -10.13% | -18.25% |
| EPS Basic | 76.35% | 85.91% | 89.05% | 70.30% | 63.71% |
| Normalized Basic EPS | 75.18% | 85.43% | 88.76% | 69.56% | 65.42% |
| EPS Diluted | 76.35% | 85.91% | 89.05% | 70.30% | 63.71% |
| Normalized Diluted EPS | 75.18% | 85.43% | 88.76% | 69.56% | 65.42% |
| Average Basic Shares Outstanding | 130.28% | 293.94% | 857.44% | 710.96% | 779.90% |
| Average Diluted Shares Outstanding | 130.28% | 293.94% | 857.44% | 710.96% | 779.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |